Quick Answer
CG Oncology, Inc. reported Net Income Loss of -$161.00 million for the year ending 2025.
- CG Oncology, Inc. showed a decrease of -82.9% in Net Income Loss from 2024 to 2025.
- This data is from CG Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$8.67 million | Q2 2023: -$11.61 million | Q3 2023: -$11.77 million | Q1 2024: -$16.93 million | Q2 2024: -$18.90 million | Q3 2024: -$20.41 million | Q1 2025: -$34.45 million | Q2 2025: -$41.43 million | Q3 2025: -$43.81 million.
- Over the full 3 years of available data (2023 to 2025), CG Oncology, Inc.'s Net Income Loss has declined by 231.2%.
- Historical annual values: Fiscal year 2025: -$161.00 million | Fiscal year 2024: -$88.04 million | Fiscal year 2023: -$48.61 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: